Tarsons Products Limited
NSE: TARSONSINE144Z01023·Healthcare·www.tarsons.com ↗·Mcap ₹1,788 Cr·Listed 2021
₹332.75▼ ₹2.70  (−0.80%)
52W: ₹164 – ₹375 · Vol: 97.1K shares · Close 25 Sept
Set Alert
Overlay:
daily candles · adjustedloading full history…Charts by TradingView
Ask the chart: “Has this stock recovered from similar drawdowns before?”
Annual report FY26 — 16.06 MB · Shareholding pattern — Jun 2026 · All filings
AI equity note (bull/bear, numbers, sources) — coming soon
Management guidance consistency — coming soon

Latest filings

NSE announcements · newest first
Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Trading window24 Sept 2026 PDF
Schedule of meet
Investor meet24 Sept 2026 PDF
Proceedings of Annual General Meeting held on September 24, 2026
AGM / EGM24 Sept 2026 PDF
Significant increase in volume has been observed in Tarsons Products Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Tarsons Products Limited has submitted their response.
Exchange clarification21 Sept 2026 PDF
Significant increase in volume has been observed in Tarsons Products Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written to the company. The response from the company is awaited.
Exchange clarification21 Sept 2026
All filings →
P/E (TTM)
159.6×
EPS ₹2.09
P / Book
2.79×
BVPS ₹119
ROE
2.3%
FY26, avg equity
Net margin
3.4%
FY26
Revenue YoY
+20.7%
Q1 FY27
Net profit YoY
−181.0%
Q1 FY27
Debt / equity
0.60×
₹383 Cr debt
Div. yield
–
no dividend in 12 months
From NSE filings (consolidated) and the last close.
Shareholding Pattern Jun 2026
Promoters
47.3%—
FIIs
0.2%▼ 0.71
DIIs
0.1%▼ 0.09
Retail
22.6%▲ 1.04
Others
29.9%▼ 0.24
Promoter pledge: none reported
Peer Comparison
CompanyP/EP/BROEMargin
POLYMED₹17,478 Cr55.9×5.63×10.9%17.1%
MOLBIO₹15,101 Cr––––
FISCHER₹2,244 Cr75.3×5.82×8.0%10.1%
TARSONS₹1,770 Cr159.6×2.79×2.3%3.4%
LAXMIDENTL₹1,094 Cr35.4×4.50×12.8%10.4%
FABTECH₹648 Cr15.2×1.54×9.1%9.3%
Medical Equipment & Supplies: the companies closest in market value, of the 7 in that basic industry whose filings we hold. Computed from each company's NSE filings (up to Q1 FY27) and the last close; hover a column for its definition.
Forensic Flags3 Watch
Free cash flow was negative in 4 of the last 4 years
Operating cash flow less capital expenditure, as filed.
Profit before interest and tax covers finance costs 2.0×
FY26.
Other income is 110% of profit before tax
FY26.
Debt to equity is 0.60×
As at 2026-03-31.
Exceptional items above 5% of pre-tax profit in 1 of the last 4 years
FY22–FY26.
8 checks within their thresholds
Operating cash flow was 2.24× net profit
Cumulative over FY22–FY26 (4 years).
Receivables grew 7% against revenue growth of 8%
FY26: debtor days moved from 74 to 74.
Inventory grew 3% against revenue growth of 8%
FY26: inventory days moved from 117 to 112.
Effective tax rate averaged 32%
Tax over pre-tax profit, last 3 years. The base corporate rate is about 25%.
Promoter holding is 47.30%, -0.01 points over a year
2026-06-30 against 2025-06-30.
No promoter shares are pledged
Shareholding pattern as at 2026-06-30.
No auditor change or resignation filings in three years
From NSE announcements on record.
Results were filed late in 0 of the last 8 quarters
Slowest filing came 58 days after the period end.
Computed from NSE filings (consolidated). Colours follow fixed thresholds, shown on hover. These are facts about the filings, not advice. 1 check not run for lack of data.
Formula Scores
Piotroski F-score: 6 of 9 · FY to 2026-03-31
one point for each of nine tests on profitability, leverage and liquidity, and operating efficiency, comparing the year with the one before
  • ✓ Return on assets positive: 1.33 — profit after tax over the year's opening total assets, %
  • ✓ Operating cash flow positive: 118.5 — ₹ crore
  • ✓ Cash flow above profit (accruals): 104.2 — operating cash flow less profit after tax, ₹ crore
  • ✗ Return on assets improved: -1.74 — change in ROA, percentage points
  • ✓ Long-term borrowings to assets fell: -1.3 — change in long-term borrowings over total assets, percentage points
  • ✗ Current ratio improved: -0.37 — change in current assets over current liabilities
  • ✓ No new shares issued: 0 — change in share capital, %
  • ✓ Gross margin improved: 3.12 — revenue less material cost over revenue, change in percentage points
  • ✗ Asset turnover improved: -0.012 — revenue over the year's opening total assets, change
Inputs: profit after tax ₹14 Cr (2026-03-31) · profit after tax ₹30 Cr (2025-03-31) · total assets ₹1,186 Cr (2026-03-31) · total assets ₹1,080 Cr (2025-03-31)
The paper's bands: 8–9: the paper's high group; 0–2: the paper's low group
Source: Joseph Piotroski, "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers", Journal of Accounting Research, 2000
Altman Z-score: 3.16 · FY to 2026-03-31
Z = 1.2 × working capital / total assets + 1.4 × retained earnings / total assets + 3.3 × EBIT / total assets + 0.6 × market value of equity / total liabilities + 1.0 × sales / total assets
  • working capital / total assets: 0.001 × 1.2
  • retained earnings / total assets: 0.526 × 1.4 — reserves and surplus as retained earnings
  • EBIT / total assets: 0.037 × 3.3 — profit before tax plus finance cost
  • market value of equity / total liabilities: 3.244 × 0.6 — market capitalisation over total assets less equity
  • sales / total assets: 0.356 × 1
Inputs: total assets ₹1,186 Cr (2026-03-31) · current assets ₹266 Cr (2026-03-31) · current liabilities ₹264 Cr (2026-03-31) · reserves ₹624 Cr (2026-03-31) · total equity ₹635 Cr (2026-03-31) · profit before tax ₹22 Cr (2026-03-31) · finance cost ₹23 Cr (2026-03-31) · revenue ₹423 Cr (2026-03-31) · market capitalisation (today) ₹1,788 Cr
The paper's bands: above 2.99: the paper's safe zone; 1.81–2.99: the grey zone; below 1.81: the distress zone
the 1968 form, fitted on manufacturers; reserves stand in for retained earnings, and profit before tax plus finance cost for EBIT
Source: Edward Altman, "Financial Ratios, Discriminant Analysis and the Prediction of Corporate Bankruptcy", Journal of Finance, 1968
Graham number: 84.97 ₹ per share · FY to 2026-03-31
√(22.5 × earnings per share × book value per share): the price at which P/E × P/B = 22.5 (a P/E of 15 at a P/B of 1.5)
  • earnings per share: 2.69
  • book value per share: 119.29 — owners' equity over shares (paid-up capital / face value)
Inputs: earnings per share 2.69 (2026-03-31) · owners' equity ₹635 Cr (2026-03-31) · paid-up capital ₹11 Cr (2026-03-31) · face value 2 (2026-03-31)
a number the book uses as a ceiling for a defensive investor's purchase price; it is arithmetic on two reported figures, not a valuation
Source: Benjamin Graham, The Intelligent Investor (1949; the 22.5 in the 1973 edition's criteria for the defensive investor)
Sloan accrual ratio: -9.19 % of assets · FY to 2026-03-31
(profit after tax − operating cash flow) / average total assets
Inputs: profit after tax ₹14 Cr (2026-03-31) · operating cash flow ₹118 Cr (2026-03-31) · total assets ₹1,186 Cr (2026-03-31) · total assets ₹1,080 Cr (2025-03-31)
how much of the year's profit was not cash; the paper sorts companies by this and reports the top decile's later returns
Source: Richard Sloan, "Do Stock Prices Fully Reflect Information in Accruals and Cash Flows about Future Earnings?", The Accounting Review, 1996
Each score is its published formula applied to the company's own filings (consolidated); open one for the tests, the inputs and the paper. Arithmetic on the filings, not a view on the stock.